Journal of Oncology Practice Launches New Blog to Facilitate Discussions on Care Delivery Topics

The Journal of Oncology Practice (JOP) launched a new care delivery blog, JOP DAiS (Discussion & Analysis in Short), to serve as a forum for commentary and analysis on issues affecting the mechanisms of oncology care delivery. This new platform will be a way to collaborate, debate, and discuss many of the topics JOP addresses in its publication including health services research, business and socioeconomics, ethics, and health policy.

Roles of a Principal Investigator Highlighted in the Journal of Oncology Practice

A new review article in the Journal of Oncology Practice reexamines the roles of a principal investigator in the current environment of rapid drug discovery and development. The review outlines the increasing responsibilities of a principal investigator, the important role they play in compliance, and how those in the field can prepare to become a successful principal investigator.

New State of Cancer Care in America Article Provides Update on the Oncology Practice Landscape

On June 15, the Journal of Oncology Practice published an ASCO article examining the state of oncology practice in the United States as part of its new State of Cancer Care in America™ article series. The State of Oncology Practice in America, 2018 reports on important trends in oncology practice ownership, practice concerns, and the oncology workforce, along with details on the size, geographical distribution, and number of practices currently open in the United States.

FDA Approves Bevacizumab for Ovarian Cancer and Pembrolizumab for Large B-Cell Lymphoma Cancer

On June 13, 2018, the Food and Drug Administration approved bevacizumab (Avastin®, Genentech, Inc.) for patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer in combination with carboplatin and paclitaxel, followed by single-agent bevacizumab, for stage III or IV disease after initial surgical resection. The FDA also accelerated approval to pembrolizumab (Keytruda®, Merck) for the treatment of adult and pediatric patients with refractory primary mediastinal large B-cell lymphoma (PMBCL), or who have relapsed after two or more prior lines of therapy.

FDA Approves Pembrolizumab for Advanced Cervical Cancer with Disease Progression During or After Chemotherapy

On June 12, 2018, the Food and Drug Administration approved pembrolizumab (Keytruda®, Merck and Co. Inc.) for patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-approved test.

Right-to-Try or Right-to-Ask? Learn What the New Federal Law Means to Your Practice and Patients in this ASCO in Action Podcast.

Right-to-try is the latest topic addressed in the ASCO in Action podcast series. ASCO CEO Dr. Clifford Hudis recently interviewed ASCO Senior Vice President and Chief Medical Officer Dr. Richard Schilsky to examine RTT legislation—now enacted as federal law—and discuss the Food and Drug Administration’s (FDA) expanded access program.

At AMA Leadership Meeting, ASCO Advocates Will Urge Action on Cancer Policy Priorities

From June 9 – 13, ASCO’s delegates will participate in the American Medical Association’s (AMA) Annual Meeting of the House of Delegates (HOD). The AMA HOD is the principal policy-making body of AMA, and meets twice a year to discuss pressing issues and establish association policies. ASCO currently sends three delegates to the AMA HOD: Edward P. Balaban, DO, FACP, FASCO; Thomas A. Marsland, MD, FASCO; and Ray D. Page, DO, PhD, FACOI.


Subscribe to ASCO RSS